Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018

BACKGROUND: A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) was developed as part of efforts to prevent frequent meningitis outbreaks in the African meningitis belt. The MACV was first used widely and with great success, beginning in December 2010, during initial deployment i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bwaka, Ado, Bita, André, Lingani, Clément, Fernandez, Katya, Durupt, Antoine, Mwenda, Jason M, Mihigo, Richard, Djingarey, Mamoudou H, Ronveaux, Olivier, Preziosi, Marie-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822965/
https://www.ncbi.nlm.nih.gov/pubmed/31671448
http://dx.doi.org/10.1093/infdis/jiz336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822965/
https://www.ncbi.nlm.nih.gov/pubmed/31671448
http://dx.doi.org/10.1093/infdis/jiz336

Ejemplares similares